Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone858-617-7600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$161.63 million
Profitability
Miscellaneous
Employees400
OptionableOptionable
Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions
What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
How were Neurocrine Biosciences' earnings last quarter?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Monday, November, 5th. The company reported $0.52 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.48 by $0.04. The firm earned $151.80 million during the quarter, compared to analysts' expectations of $151.51 million. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. The company's quarterly revenue was up 149.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.13) EPS. View Neurocrine Biosciences' Earnings History.
When is Neurocrine Biosciences' next earnings date?
How can I listen to Neurocrine Biosciences' earnings call?
Neurocrine Biosciences will be holding an earnings conference call on Tuesday, February 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8778769174.
What price target have analysts set for NBIX?
18 brokers have issued 12-month target prices for Neurocrine Biosciences' shares. Their forecasts range from $17.07 to $135.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $101.2817 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.
What is the consensus analysts' recommendation for Neurocrine Biosciences?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 1 hold rating and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.
What are Wall Street analysts saying about Neurocrine Biosciences stock?
Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
- 1. HC Wainwright analysts commented, "Our price target of $102/share is based on an equally weighted composite of: (a) $103/share, as a 35x multiple of taxed and diluted FY25 GAAP EPS of $8.80 discounted back to and (b) an NPV of $101/share (discount rate 10%, growth rate 2%). We base our valuation on a 20% royalty on sales for Elagolix in endometriosis and uterine fibrosis (probability adjusted). For valbenazine, we include the indication of TD. For opicapone, we include the US revenue (63% goes to 85% POS." (1/15/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating despite reducing our PT to $121 from $150 on shares of NBIX. Today, Neurocrine announced disappointing topline results from the T-Force GOLD study of valbenazine in Tourette’s syndrome. The study failed to meet its primary endpoint of change on the Scale (YGTSS). Although this outcome may not “prove” a lack of potential for valbe’ in TS, we need to suspend disbelief for ~12mo until the readout of T-Force PLATINUM, a randomized withdrawal designed to gain incremental visibility." (12/12/2018)
- 3. Needham & Company LLC analysts commented, "Mesoblast announced good news that remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft- versus-host disease (GvHD)." (2/22/2018)
Has Neurocrine Biosciences been receiving favorable news coverage?
Press coverage about NBIX stock has been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurocrine Biosciences earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the near future.
Who are some of Neurocrine Biosciences' key competitors?
Some companies that are related to Neurocrine Biosciences include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP) and Acceleron Pharma (XLRN).
Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the folowing people:
- Dr. Kevin C. Gorman, CEO & Director (Age 61)
- Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
- Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
- Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
- Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)
Who are Neurocrine Biosciences' major shareholders?
Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Navellier & Associates Inc (0.02%), Sit Investment Associates Inc. (0.02%), Highland Capital Management LLC (0.01%), Meeder Asset Management Inc. (0.01%), Nisa Investment Advisors LLC (0.01%) and Fox Run Management L.L.C. (0.01%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.
Which major investors are selling Neurocrine Biosciences stock?
NBIX stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Navellier & Associates Inc and Dubuque Bank & Trust Co.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Corinne H Nevinny, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.
Which major investors are buying Neurocrine Biosciences stock?
How do I buy shares of Neurocrine Biosciences?
Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurocrine Biosciences' stock price today?
One share of NBIX stock can currently be purchased for approximately $91.53.
How big of a company is Neurocrine Biosciences?
Neurocrine Biosciences has a market capitalization of $8.30 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.
What is Neurocrine Biosciences' official website?
How can I contact Neurocrine Biosciences?
Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]
MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
